Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
of Thoratec Corp.
NEW YORK, Dec. 2, 2013
NEW YORK, Dec. 2, 2013 /PRNewswire/ --Attorney Advertising --Bronstein,
Gewirtz & Grossman, LLC is investigating potential claims on behalf of
purchasers of the securities of Thoratec Corp. ("Thoratec" or the "Company")
(NasdaqGS: THOR -News). Such investors are advised to contact Peretz
Bronstein or his investor Relation's coordinator Eitan Kimelman at
email@example.com or 212-697-6484.
The investigation concerns whether Thoratec and certain of its officers and/or
directors have violated Sections 10(b) and 20(a) of the Securities Exchange
Act of 1934. On November 29, 2013 shares of Thoratec fell $2.75 or 6.53%
during intraday trading to trade at $39.37 after a report published Wednesday
in the New England Journal of Medicine said a study conducted by the Cleveland
Clinic found an increasing rate of blood clots in patients implanted with the
company's HeartMate II pump.
If you are aware of any facts relating to this investigation, or purchased
shares of Thoratec, you can assist this investigation by contacting Peretz
Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein,
Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those
who inquire by e-mail are encouraged to include their mailing address, email
and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not guarantee similar
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC
Press spacebar to pause and continue. Press esc to stop.